EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ardelyx's enterprise value is $1,374.8 Mil.
Ardelyx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $124.5 Mil. Therefore, Ardelyx's EV-to-Revenue for today is 11.05.
The historical rank and industry rank for Ardelyx's EV-to-Revenue or its related term are showing as below:
ARDX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.21 Med: 9.94 Max: 960.32
Current: 11.05
During the past 12 years, the highest EV-to-Revenue of Ardelyx was 960.32. The lowest was -2.21. And the median was 9.94.
ARDX's EV-to-Revenue is ranked worse than 58.7% of 1034
companies
in the Biotechnology industry
Industry Median: 7.775
vs ARDX: 11.05
As of today (2024-05-01), Ardelyx's stock price is $6.391.
Ardelyx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.55. Therefore, Ardelyx's PS Ratio for today is 11.54.
Ardelyx EV-to-Revenue Historical Data
The historical data trend for Ardelyx's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ardelyx's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ardelyx's EV-to-Revenue falls into.
Ardelyx's current Enterprise Value is $1,374.8 Mil.
Ardelyx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $124.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx's share price for today is $6.391.
Ardelyx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ardelyx's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARDX has been successfully added to your 